Register entry
Deciphera Pharmaceuticals, LLC
- Registered sites
- 0
- Drug products
- 4
- Live patents
- 80
- Countries
- 0
- Base
- Unknown
Sites
Facilities
0No registered facilities
This company holds drug listings or approvals but operates no registered establishment of its own, which is normal for an NDA holder that outsources manufacturing.
Exclusivity
Patents
80Unexpired Orange Book patents where this company is the application holder.
| Product | Active ingredient | Expiry |
|---|---|---|
| QINLOCK | RIPRETINIB | Jul 2030 |
| QINLOCK | RIPRETINIB | Jun 2032 |
| QINLOCK | RIPRETINIB | May 2034 |
| QINLOCK | RIPRETINIB | Aug 2040 |
| QINLOCK | RIPRETINIB | Dec 2040 |
| QINLOCK | RIPRETINIB | Feb 2041 |
| QINLOCK | RIPRETINIB | Oct 2042 |
| ROMVIMZA | VIMSELTINIB | Mar 2034 |
| ROMVIMZA | VIMSELTINIB | Dec 2039 |
| ROMVIMZA | VIMSELTINIB | Feb 2040 |
| ROMVIMZA | VIMSELTINIB | Dec 2044 |
| ROMVIMZA | VIMSELTINIB | Apr 2045 |
Catalogue
Marketed products
4Showing 4 of 4.
| Brand | Generic name | Form | Category |
|---|---|---|---|
| QINLOCK | Ripretinib | TABLET | NDA |
| ROMVIMZA | Vimseltinib | CAPSULE | NDA |
| ROMVIMZA | Vimseltinib | CAPSULE | NDA |
| ROMVIMZA | Vimseltinib | CAPSULE | NDA |
Provenance
Facility and operations data from the FDA Drug Establishments Current Registration Site. Product data from the openFDA National Drug Code Directory. Patent and exclusivity data from the FDA Orange Book. Shortage data from the FDA drug shortage database. Contact details the FDA publishes for registered establishments are deliberately not reproduced here. This entry is compiled from public records and has not been claimed by the company.